The National Public Health Emergency Team is expected to issue an update in relation to the use of the Astra Zeneca vaccine today following meetings with the National Immunization Advisory Committee and the Health Products Regulatory body later this morning.
An investigation by the European Medicines Agency concluded that the vaccine is not associated with an increase in the overall risk of blood clots in those who receive it, but that it may be associated with very rare clots in vessels draining blood from the brain.
The EMA said the benefits of the vaccine continue to outweigh the risk of side effects but that product information for the vaccine should be updated to include more information on these risks.